The present study aimed to evaluate the stability of active pharmaceutical ingredients (APIs) from different pharmacological classes in a compounded oral suspending vehicle. Oral suspensions amoxicillin trihydrate (50 mg/mL), clozapine (25 indomethacin (5.0 levodopa/carbidopa (10.0/2.5 levothyroxine sodium (T4, 25 µg/mL), lomustine (4.0 and 10.0 methyldopa mg/mL) procarbazine (10.0 were formula...

The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced, progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control In medicine, it is not infrequent that treatments in different institutions evolve over a period of time, by accepted use, with modest background data. In the realm of palliative chemotherapy, it is clear t...

Owners of dogs with cancer are often offered chemotherapeutic treatment. However, clients who seek veterinary care for pets with cancer are often concerned about the potential negative impact of chemotherapeutic treatments on their animals’ quality of life. The purpose of this retrospective case series was to investigate the delayed acute effects of chemotherapy drugs in dogs receiving cancer t...

The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was ...

The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and...

Abstract BACKGROUND Thrombocytopenia represents the main cause of stopping chemotherapy for toxicity during treatment glioblastoma. Here we explored incidence and prognostic implications lomustine modification thrombocytopenia in recurrent METHODS We retrospectively analysed thrombocytopenia, its consequences delivery, associations with outcome phase II III parts EORTC 26101, a randomized trial...